Clinical trialRSSMay 15
Phase 3 trial of solengepras for Parkinson’s disease now fully enrolled
A large clinical trial testing a new Parkinson's disease medication called solengepras has finished enrolling 341 patients. This medication works differently than standard Parkinson's drugs and is being tested alongside regular treatments to see if it helps patients who experience movement problems that come and go throughout the day.
WHY IT MATTERSIf solengepras proves effective in this Phase 3 trial, it could offer Parkinson's patients a new treatment option that works through a different mechanism than current dopamine-based therapies, potentially helping those with motor fluctuations who don't respond adequately to standard medications alone.